Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 26;12:1629–1640. doi: 10.2147/OTT.S196713

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Gao et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

ARQ-197 enhances the antitumor effect of sorafenib on the subcutaneous growth of MHCC97-H cells in nude mice.

Notes: MHCC97-H cells were seeded into nude mice to form subcutaneous tumors. Nude mice received oral administration of solvent control, ARQ-197, sorafenib, or ARQ-197 + sorafenib. Tumors were harvested and tumor volumes or tumor weights were noted. Results are shown as photographs of subcutaneous tumors (A), tumor volumes (B), inhibition rates of agents on MHCC97-H cells’ subcutaneous growth calculated from tumor volumes (C), or tumor weights (D), orinhibition rates of agents on MHCC97-H cells’ subcutaneous growth calculated from tumor weights (E). ^*P<0.05.

ARQ-197 enhances the antitumor effect of sorafenib on the subcutaneous growth of MHCC97-H cells in nude mice.

Notes: MHCC97-H cells were seeded into nude mice to form subcutaneous tumors. Nude mice received oral administration of solvent control, ARQ-197, sorafenib, or ARQ-197 + sorafenib. Tumors were harvested and tumor volumes or tumor weights were noted. Results are shown as photographs of subcutaneous tumors (A), tumor volumes (B), inhibition rates of agents on MHCC97-H cells’ subcutaneous growth calculated from tumor volumes (C), or tumor weights (D), orinhibition rates of agents on MHCC97-H cells’ subcutaneous growth calculated from tumor weights (E). ^*P<0.05.